Integra LifeSciences Q3 adjusted EPS seen at $0.55-$0.59; revenue seen at $410-$412 million

Bitget2026/10/02 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Integra LifeSciences expects Q3 2026 revenue of about $410 million-$412 million; adjusted EPS seen at $0.55-$0.59.
Flooding-related supply disruption is estimated to have reduced Q3 revenue by about $7 million; Q4 revenue hit seen at $15 million-$20 million.
Full-year 2026 revenue outlook cuts to $1.634 billion-$1.654 billion; adjusted EPS guidance lowered to $2.30-$2.40.
Operating cash flow still projected at about $190 million-$200 million for 2026; Q3 operating cash flow expected above $85 million.
Cincinnati site expected to return to full manufacturing operations in Q2 2027; insurance recoveries expected to offset a substantial portion of earnings impact.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Integra LifeSciences Holdings Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020805PRIMZONEFULLFEED9838446) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Integra LifeSciences Q3 adjusted EPS seen at $0.55-$0.59; revenue seen at $410-$412 million

You may also like

Crypto prices